Questo sito utilizza cookie, propri e di altri siti, solo al fine di garantire una navigazione ottimale e di raccogliere statistiche anonime sui dati di navigazione senza alcuna profilazione dell’utente.

Se vuoi saperne di più o negare il consenso a tutti o ad alcuni cookie clicca qui.

Se accedi a un qualunque elemento sottostante questo banner acconsenti automaticamente all’uso dei cookie.

Accetto

Toxicogenomics

Drug attrition rate in clinical trials is almost 90% and is primarily due to the high incidence of adverse effects. We offer an early-stage toxicity assessment tool that integrates with small, non-GLP, preclinical conventional toxicology and improves predictivity of such studies in combination with well established toxicological parameters.


Toxicogenomics has the potential to be used as a key decision tool in drug discovery and development. Toxicogenomics is the study of drug related safety/toxicity at the gene expression level and helps to:

  • understand mechanisms of toxicity
  • suggest off-target activities of the drug
  • predict toxic effects in an early stage of development
  • discover predictive markers of toxicity